Intellia Therapeutics, which has raised $85m in under 18 months from backers including Novartis, has signed a collaboration agreement with Regeneron and filed for a $120m IPO.

Biopharmaceutical company Regeneron Pharmaceuticals has agreed to invest $75m in the next funding round raised by Intellia Therapeutics, a US-based gene editing technology developer that has filed for a $120m initial public offering.

Intellia is working on drugs based on the Crispr/Cas9 gene editing system, which can cut DNA in specific locations, making it possible to remove, repair or insert specific genetic sequences.

Regeneron pledged the equity funding as part of a licensing and collaboration agreement to advance Crispr/Cas gene-editing…